Status:
RECRUITING
MIVetsCan: Cannabidiol (CBD)-Care Trial
Lead Sponsor:
Kevin Boehnke
Collaborating Sponsors:
Michigan, State of, Licensing and Regulatory Affairs
Conditions:
Pain, Chronic
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This research is studying the effects of cannabidiol (CBD), an active component from cannabis (a.k.a. marijuana), on Veterans' chronic pain. The purpose of this study is to better understand if CBD ca...
Eligibility Criteria
Inclusion
- Ability to read and speak English sufficiently to allow for written informed consent and patient-reported outcomes measures
- Armed Services Veteran
- All participants must have been enrolled in the MIVetsCan Pain Registry (HUM00223894) for at least 4 weeks and agree to continue participation in that study.
- Reports moderate to severe chronic pain defined by protocol
- Currently using or interested in using cannabis for pain management
- Self-reported willingness to refrain from or not increase current Tetrahydrocannabinol (THC) or other cannabis product use (including CBD) during the study intervention or other cannabinoid use during the study intervention
- Individuals of reproductive potential must agree to use acceptable birth control per protocol
- Participants must also agree not to donate sperm or eggs during study drug administration
- Willingness to attend all study visits (may be done virtually)
- Ability to take and to swallow the study medication and be willing to adhere to the treatment regimen
- Willingness to wear Fitbit or other similar sensor for passive-data collection
- Willingness to fill out daily diary via smartphone to assess symptom status, study drug use, and other cannabis use
Exclusion
- Not an Armed Services Veteran
- Inability to provide informed consent (e.g., cognitive impairment, unable to sufficiently communicate in English)
- Participant reports pregnancy or are nursing
- Planning to move out of a state with legal recreational marijuana use during course of study
- Risk for imminent harm - Suicidal ideation or wish to die as assessed per protocol
- Any impairment, activity, behavior, or situation that in the judgment of the study team would prevent satisfactory completion of the study protocol
- Participation in any other clinical trials over the course of this study
- Medical or psychiatric conditions that in the judgment of study personnel would preclude participation in this study (e.g., psychosis, suicidal ideation; note that stable anxiety and depression are not exclusions)
- Having a serious or unstable hepatic disease (e.g., non-alcoholic fatty liver disease or liver cirrhosis)
- Individuals with major neurological disorders, such as dementia, Parkinson's disease, cognitive impairment, epilepsy, and seizures
- Recent/new diagnosis of cancer within the past 3 years (other than localized melanoma, localized basal cell carcinoma, localized squamous cell carcinoma treated or untreated)
- Current valproate and clobazam use per self-report or medical records
- Self-reported allergies to sesame oil or cannabis/cannabinoids
Key Trial Info
Start Date :
February 12 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
468 Patients enrolled
Trial Details
Trial ID
NCT06213233
Start Date
February 12 2024
End Date
December 1 2026
Last Update
May 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan
Ann Arbor, Michigan, United States, 48109